Market Trends of Endometrial Ablation Devices Industry
This section covers the major market trends shaping the Endometrial Ablation Devices Market according to our research experts:
Radiofrequency Endometrial Ablation Device is Expected to Hold Significant Share in the Market Over The Forecast Period
Radiofrequency ablation devices are used to transmit radio frequency energy and destroy the tissue lining the uterus (the endometrium). These devices ensure a reduced risk of infection. The notable share of radiofrequency endometrial ablation devices is accounted for by factors such as high safety and fast recovery, increasing awareness related to this technique in developing countries, and high preference from several medical practitioners. Apart from the advantages of the devices, the factors driving segment growth are the increasing prevalence of cervical cancer, menorrhagia, and other gynecologic disorders.
According to the NCBI study published in August 2022, in the clinical trial conducted to test the safety and efficacy of the Cerene device, a radiofrequency endometrial ablation device, 91% of the enrolled subjects reported that they had no limitations in the activity of the device, and 85% of the subjects were satisfied with the performance of the device. Thus, the higher safety and efficacy of the radiofrequency ablation system are expected to increase segment growth over the forecast period. Moreover, the growing prevalence of endometrial cancer is expected to boost segment growth. As per the ACS 2022 update, there were more than 600,000 survivors of endometrial cancer in the United States. According to the same source, around 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) are expected to be diagnosed in 2022. Thus, the growing prevalence of endometrial cancer is expected to increase demand for endometrial ablation devices.
Additionally, the increasing number of product approvals is also expected to contribute to the growth of the market. For instance, in September 2021, Gynesonics received approval from the US FDA for their next-generation Sonata System 2.2 radiofrequency ablation of fibroid tumors. This Sonata technology platform integrates a commercial intrauterine ultrasound system with an advanced radiofrequency ablation device to provide incision-free, uterus-preserving treatment. Thus, the high safety and efficiency of the radiofrequency endometrial ablation devices and the approval of the advanced products are expected to contribute to the growth of the studied segment.
North America is Expected to Hold Significant Share in the Market Over the Forecast Period
North America is expected to hold a significant share of the overall market throughout the forecast period. Escalating cases of gynecological disorders, rising healthcare infrastructure, and the strong establishment of major market players to offer innovative endometrial ablation devices are accountable for promoting the endometrial ablation devices market in this region. According to the NCBI study published in May 2022, endometriosis is a chronic inflammatory pain disorder that affects 6.5 million women in the United States each year. Additionally, the data published by the Canadian Cancer Society in 2022 mentioned that an estimated 1,450 Canadian women will be diagnosed with cervical cancer in 2022. Hence, the growing prevalence of endometritis and gynecological disorders in this region is expected to drive the demand for endometrial ablation devices, thereby contributing to the growth of the market in this region.
Additionally, key market players' strategies, such as acquisitions and mergers, and rising investments support market growth. For instance, in October 2021, Hologic, Inc. acquired Bolder Surgical for approximately USD 160 million. The complementary acquisition of Bolder Surgical added to the Hologic surgical product line, which includes the Novasure endometrial ablation system for the treatment of abnormal uterine bleeding. Also, in February 2022, CooperSurgical agreed to spend USD 875 million on Cook Medical's reproductive health portfolio, which includes fertility, obstetrics, gynecology, and in vitro fertilization medical equipment.
